ArticleJournal of cellular and molecular medicine2016

CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies.

Annette Romanski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.